Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 2
1987 2
1988 1
1990 1
1992 2
1993 4
1994 1
1995 2
1996 5
1997 4
1998 2
1999 2
2000 4
2001 1
2003 3
2004 1
2005 3
2006 1
2007 1
2011 3
2012 3
2014 2
2016 1
2017 1
2020 1
2024 1
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ser more in IGF-1 growth hormone (7 results)?
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Rahman OF, Lee SJ, Seeds WA. Rahman OF, et al. J Am Acad Orthop Surg Glob Res Rev. 2026 Jan 2;10(1):e25.00236. doi: 10.5435/JAAOSGlobal-D-25-00236. eCollection 2026 Jan 1. J Am Acad Orthop Surg Glob Res Rev. 2026. PMID: 41490200 Free PMC article. Review.
Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-960 …
Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibr …
Growth hormone releasing hormone.
Grossman A, Savage MO, Besser GM. Grossman A, et al. Clin Endocrinol Metab. 1986 Aug;15(3):607-27. doi: 10.1016/s0300-595x(86)80012-3. Clin Endocrinol Metab. 1986. PMID: 2429796 Review.
Human growth hormone releasing hormone (GHRH) was originally extracted from two pancreatic tumours in patients with acromegaly, and is now known to consist of a 44 residue amidated peptide or its C-terminal-shortened derivatives. ...Early studies also indicat …
Human growth hormone releasing hormone (GHRH) was originally extracted from two pancreatic tumours in patients with acr …
Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.
Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, Herati A, Lindgren MC, Lipshultz LI. Sigalos JT, et al. Am J Mens Health. 2017 Nov;11(6):1752-1757. doi: 10.1177/1557988317718662. Epub 2017 Aug 22. Am J Mens Health. 2017. PMID: 28830317 Free PMC article.
Realizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endogenous GH is needed. Several GH secretagogues are available, including GH-releasing peptides (GHRPs) GHRP-2 and GHRP-6, and the GH-releasing …
Realizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endog …
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Sinha DK, et al. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. Transl Androl Urol. 2020. PMID: 32257855 Free PMC article. Review.
The GHS that will be discussed include sermorelin, growth hormone-releasing peptides (GHRP)-2, GHRP-6, ibutamoren, and ipamorelin. All are potent GH and IGF-1 stimulators that can significantly improve body composition while ameliorating specifi …
The GHS that will be discussed include sermorelin, growth hormone-releasing peptides (GHRP)-2, GHRP-6, ibutamoren, and …
PEGylation of growth hormone-releasing hormone (GRF) analogues.
Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM. Esposito P, et al. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1279-91. doi: 10.1016/s0169-409x(03)00109-1. Adv Drug Deliv Rev. 2003. PMID: 14499707 Review.
It maintains bioactivity in vitro and is almost equally effective in eliciting secretion of endogenous growth hormone in vivo. The main drawbacks associated with the pharmaceutical use of hGRF1-29 relate to its short half-life in plasma, about 10-20 min in humans, w …
It maintains bioactivity in vitro and is almost equally effective in eliciting secretion of endogenous growth hormone in vivo. …
Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone.
Neyzi O, Yordam N, Ocal G, Bundak R, Darendeliler F, Açikgöz E, Berberoğlu M, Günöz H, Saka N, Calikoğlu AS. Neyzi O, et al. Acta Paediatr Suppl. 1993 Mar;388:16-21; discussion 22. doi: 10.1111/j.1651-2227.1993.tb12828.x. Acta Paediatr Suppl. 1993. PMID: 8329826 Clinical Trial.
To assess the growth-promoting effect of different doses of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in GH deficiency (GHD) of hypothalamic origin, 43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) wer …
To assess the growth-promoting effect of different doses of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-2 …
Treatment of growth-hormone deficiency with growth-hormone-releasing hormone.
Ross RJ, Rodda C, Tsagarakis S, Davies PS, Grossman A, Rees LH, Preece MA, Savage MO, Besser GM. Ross RJ, et al. Lancet. 1987 Jan 3;1(8523):5-8. doi: 10.1016/s0140-6736(87)90699-4. Lancet. 1987. PMID: 2879138
18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2. ...In the 14 patients who had previously received human GH (hGH) height …
18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth …
Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women.
Khorram O, Yeung M, Vu L, Yen SS. Khorram O, et al. J Clin Endocrinol Metab. 1997 Nov;82(11):3590-6. doi: 10.1210/jcem.82.11.4363. J Clin Endocrinol Metab. 1997. PMID: 9360512 Clinical Trial.
Aging in humans is associated with the decline of functional activities of the GH-insulin-like growth factor I (IGF-I) axis and the immune system. Because lymphocytes express GH-IGF-I, as well as GHRH and their respective receptors, restoration …
Aging in humans is associated with the decline of functional activities of the GH-insulin-like growth factor …
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours.
Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G. Szepeshazi K, et al. Eur J Cancer. 2000 Jan;36(1):128-36. doi: 10.1016/s0959-8049(99)00230-0. Eur J Cancer. 2000. PMID: 10741306
Insulin-like growth factors (IGF-I and IGF-II) are implicated in the pathogenesis of pancreatic carcinoma. Antagonists of growth hormone-releasing hormone (GH-RH) suppress the GH-RH-GH-IGF-I axis and also act directly on tumours to reduce production of …
Insulin-like growth factors (IGF-I and IGF-II) are implicated in the pathogenesis of pancreatic carcinoma. Antagonists of growth …
A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency.
Chen RG, Shen YN, Yei J, Wang CF, Xie DH, Wang XH, Zhou JD, Chen CY, Wu YL, Gunnarsson R, et al. Chen RG, et al. Acta Paediatr Suppl. 1993 Mar;388:32-5; discussion 36. doi: 10.1111/j.1651-2227.1993.tb12834.x. Acta Paediatr Suppl. 1993. PMID: 8329830 Clinical Trial.
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or gr …
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal …
57 results